UnitedHealth Group Incorporated (UNH) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, UNH scores 65 out of 100, earning a C grade and the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The Fundamental Cash Engine pillar scores 14 of 20, supported by an ROIC of 11.5% and an FCF yield of 6.48%, indicating solid cash generation relative to the share price. The Whale 13F Flow pillar scores 11 of 20, reflecting institutional accumulation and options positioning that is constructive but not dominant. The Insider Conviction pillar scores 13 of 20, reflecting Form 4 and Congressional flow that is mixed, with recent insider activity skewing toward sales in the holders data. The Macro Regime Fit pillar scores 11 of 20, with a Beta of 0.33 per the market data, implying low market sensitivity alongside sector-level sensitivity the rating flags without further detail. The Forensic Balance Sheet pillar scores 16 of 20, supported by an Altman Z-Score of 3.12, a Piotroski F-Score of 7/9, and Debt/Equity of 0.7. For a prospective investor evaluating the stock today, the upside drivers are the cash engine and balance sheet strength; the valuation tradeoff is a trailing P/E of 25.8 versus a forward P/E of 17.7, which implies that the outlook embedded in the forward figure is materially more favorable than trailing results; and the second-order risks run through Medicare and Medicaid reimbursement and pharmacy cost dynamics described in the supply-chain data.

Per the profile, UnitedHealth Group is described as the largest vertically integrated U.S. healthcare enterprise, operating in the Health Care sector and the Managed Health Care, Medicare Advantage & Optum Services industry on the NYSE. Its UnitedHealthcare segment provides insurance benefits across commercial, Medicare Advantage, and Medicaid populations. Optum Health delivers value-based physician care, OptumRx operates pharmacy benefit management, and Optum Insight provides health IT analytics. Per the Butterfly Supply-Chain Graph, the largest customer exposures are CMS (Medicare Advantage and state Medicaid agencies) at 44% of revenue and self-insured employers and commercial sponsors at 38%.

Per the SEC financials, quarterly revenue ran between $111721.0M and $113215.0M across the four reported periods, while net income ranged from $10.0M in Q4 2025 to $6280.0M in Q1 2026, showing wide quarterly variation in profitability. Per the market data, gross margin is 88.6%, operating margin 4.8%, and net margin 3.1%, with ROIC at 11.5%. The Forensic Balance Sheet pillar of the Roarable RQD rating cites an Altman Z-Score of 3.12, a Piotroski F-Score of 7/9, and Debt/Equity of 0.7. Debt declined from $80136.0M in Q3 2025 to $73328.0M in Q2 2026 per the SEC financials.

Per the Butterfly Supply-Chain Graph, UNH's suppliers include Eli Lilly, Novo Nordisk, and branded biopharma manufacturers at 28% revenue exposure (GLP-1 and specialty biologics negotiated via OptumRx), and HCA Healthcare and acute-care hospital systems at 45% exposure (approximately 85% of the medical care ratio cost pool). Both are classified as CRITICAL. The primary 2nd-order risk identified in the graph is the GLP-1 link: label expansions into cardiovascular risk reduction, sleep apnea, and kidney disease could expand Part D specialty drug utilization faster than Medicare Advantage benchmark rates adjust, pressuring the medical care ratio until premiums reprice. The graph notes a competing explanation: OptumRx rebate retention and prior-authorization controls may partially offset gross GLP-1 spend. Competitors listed include CVS Health (85% revenue exposure, CRITICAL), Elevance Health and The Cigna Group (78%, CRITICAL), and Humana (36%, HIGH), indicating overlapping Medicare and commercial markets where pricing and reimbursement dynamics are shared. Investors should watch the CMS Part D guidance and the next medical care ratio print as the two identified near-term checkpoints.

Per the analyst data, 19 analysts rate the stock Buy, 5 Hold, and 0 Sell, with 8 of the Buy ratings being Strong Buy. The target low is $432.58, the target high is $532.69, the target mean is $491.26, and the target median is $494.44, with an implied upside of 20.71% and a Street B/S score of 73. Recent calls include Jefferies (upgrade to Strong Buy, 2026-03-27), Barclays (Buy reiterated, 2026-02-27), and Morgan Stanley (upgrade to Strong Buy, 2026-09-11). Several recent calls, including J.P. Morgan (2026-07-17) and Evercore ISI (2026-07-31), show negative returns since the call date per the analyst data.

Per the holders data, recent Form 4 insider activity consists entirely of sales, including DeVeydt Wayne S (1209 shares at 399.66, filed 2026-09-04), Conway Patrick Hugh (multiple sales, the largest 1169 shares at 390, filed 2026-08-25), and Stankiewicz Dennis Andrew (233 shares at 402.19, filed 2026-08-13). Per the same section, Berkshire Hathaway reported a 13F-HR purchase of 1250000 shares at 425.36 (total value $531700000), filed 2026-07-18. No Congressional trades are listed in the holders data.

• The source data does not explain the drivers behind the quarterly swing in net income, from $10.0M in Q4 2025 to $6280.0M in Q1 2026.
• The source data does not specify the Medical Care Ratio figures for any period, which are central to the GLP-1 and hospital cost pressure described in the supply-chain graph.
• The source data does not confirm whether the Department of Veterans Affairs award is reflected in revenue or backlog figures reported in the SEC financials.
• The source data does not detail the 52-week price range's drivers, including the move from $234.6 to $630.73 and back to a price of $410.91.
• The source data does not provide the Congressional trading activity referenced in the RQD insider pillar.